GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » ROC %

Journey Medical (Journey Medical) ROC % : -132.99% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Journey Medical ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Journey Medical's annualized return on capital (ROC %) for the quarter that ended in Mar. 2024 was -132.99%.

As of today (2024-05-28), Journey Medical's WACC % is 10.80%. Journey Medical's ROC % is 1.49% (calculated using TTM income statement data). Journey Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Journey Medical ROC % Historical Data

The historical data trend for Journey Medical's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical ROC % Chart

Journey Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
24.16 26.98 -101.58 -79.68 3.00

Journey Medical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.22 -36.49 186.20 -28.39 -132.99

Journey Medical ROC % Calculation

Journey Medical's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=1.07 * ( 1 - -6.08% )/( (44.607 + 31.11)/ 2 )
=1.135056/37.8585
=3.00 %

where

Journey Medical's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-40.36 * ( 1 - 0% )/( (31.11 + 29.587)/ 2 )
=-40.36/30.3485
=-132.99 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Journey Medical  (NAS:DERM) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Journey Medical's WACC % is 10.80%. Journey Medical's ROC % is 1.49% (calculated using TTM income statement data). Journey Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Journey Medical ROC % Related Terms

Thank you for viewing the detailed overview of Journey Medical's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Journey Medical (Journey Medical) Business Description

Traded in Other Exchanges
N/A
Address
9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.
Executives
Jeffrey Paley director C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith director C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Claude Maraoui director, officer: President & CEO C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch officer: Interim CFO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135

Journey Medical (Journey Medical) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold Journey Medical Corp Shares

By GuruFocus Research GuruFocus Editor 05-19-2023